Why these 3 ASX healthcare shares could get a boost from the federal budget

We check whether additional funding for COVID-19 testing might impact these ASX shares?

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The federal budget committed $546 million in government spending on COVID-19 PCR testing
  • That could be good news for ASX pathology shares Sonic Healthcare, Healius, and Australian Clinical Labs, according to one broker
  • Though, the broker notes that additional RATs offered to concession card holders and kids could offset some demand for PCR testing

The federal budget has, understandably, been the talk of the town today, with many market watchers questioning which shares will be budget winners and which might be less fortunate. And while ASX stocks in the retail, fuel, and automotive sectors have been in focus for various reasons, one broker is flagging a win for healthcare shares.  

So, why are ASX healthcare shares Sonic Healthcare Limited (ASX: SHL), Healius Ltd (ASX: HLS), and Australian Clinical Labs Ltd (ASX: ACL) in the post-budget spotlight? Let's take a look.

These 3 ASX healthcare shares might benefit from the budget

Broker RBC Capital Markets believes ASX healthcare shares could get a boost from extra spending on Medicare announced in the 2022/23 budget, as reported by the Australian Financial Review.

The broker is keeping an eye on ASX pathology giants on the back of a $546 million commitment to Medicare Benefits Schedule items used to conduct PCR tests.

The funding is intended to support Australia's pandemic response. However, it surprised the broker. RBC Capital Markets was quoted as saying:

The Government has extended the Medicare schedule for COVID testing.

However, the amount budgeted for 2022-23 suggests upside to our [financial year 2023] COVID testing forecasts if the budget assumptions eventuate.

Of course, more testing is likely good news for the pathology giants. Though, it might be slightly offset by more free Rapid Antigen Tests (RATs).

The government has also committed to spend another $1.6 billion to ensure all Australians have equitable access to RATs.

The broker's rose-coloured prediction didn't manage to boost the ASX healthcare giants' share prices on Wednesday.

None of the three pathology stocks significantly beat the S&P/ASX 200 Index (ASX: XJO)'s 0.67% gain.

At market close, the Sonic Healthcare share price is 0.17% higher at $35.79.

Meantime, Australian Clinical Labs ended the day in the green, gaining 0.2% to close at $5.11.

Finally, the Healius share price slightly outperformed the ASX 200 today. It rose 0.68% to finish at $4.43.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »

research with microscope
Healthcare Shares

This ASX healthcare stock just changed its debt. Here's why it matters

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

Read more »

stock growth chart
Healthcare Shares

Will CSL shares crash again in 2026?

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »

A man packs up a box of belongings at his desk as he prepares to leave the office.
Healthcare Shares

Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Telix shares storm higher on big US and China news

Let's see why this biotech is getting attention on Monday.

Read more »